J. Curwen

发表

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.

A. Rabow, D. M. Andrews, G. Walker, 2015, Journal of medicinal chemistry.

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

B. Curry, S. Wedge, J. Kendrew, 2002, Cancer research.

Novel imidazo[1,2-a]pyridine based inhibitors of the IGF-1 receptor tyrosine kinase: optimization of the aniline.

R. Ducray, J. Curwen, C. D. Jones, 2011, Bioorganic & medicinal chemistry letters.

Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src.

P. Plé, J. Curwen, L. Hennequin, 2004, Journal of medicinal chemistry.

Assessment of Vascular Reactivity Changes in Insulin Resistance and their Role in Blood Pressure Elevation

J. Curwen, 1997 .

Abstract 917: AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer

C. Chresta, S. Guichard, B. Davies, 2012 .

The Use and Refinement of Rodent Models in Anti-cancer Drug Discovery: A Review

S. Wedge, J. Curwen, 2009, Alternatives to laboratory animals : ATLA.

Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence

D. Webb, J. Curwen, D. Wilson, 2005, British Journal of Cancer.

Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy

S. Wedge, J. Kendrew, J. Curwen, 2008, Clinical Cancer Research.

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

O. Delpuech, C. Chresta, S. Guichard, 2015, Molecular Cancer Therapeutics.

Running title : Pharmacology of SERD inhibitor in breast cancer models

Graham, A. Rabow, R. A. Norman, 2016 .

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

S. Barry, S. Wedge, J. Kendrew, 2005, Cancer research.

Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats.

F. Westwood, D. Roberts, A. Ryan, 2007, Journal of the National Cancer Institute.

Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.

J. Kendrew, P. Plé, J. Curwen, 1999, Journal of medicinal chemistry.

Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.

S. Wedge, J. Kendrew, Andrew P Thomas, 2002, Journal of medicinal chemistry.

ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.

B. Curry, S. Wedge, J. Kendrew, 2000, Cancer research.

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer

J. Carroll, O. Delpuech, Rasmus Siersbaek, 2018, Molecular Cancer Therapeutics.

Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R).

Scott Boyd, S. Degorce, R. Ducray, 2016, Journal of medicinal chemistry.

In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib

M. Braddock, J. Curwen, Jianyang Wang, 2015, Pharmacology research & perspectives.

Targeting Non-Small Cell Lung Cancer Cells by Dual Inhibition of the Insulin Receptor and the Insulin-Like Growth Factor-1 Receptor

E. E. Vincent, J. Tavaré, I. Hers, 2013, PloS one.

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

N. Carragher, P. Elvin, B. Davies, 2009, Molecular oncology.

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.

L. Otterbein, J. Breed, R. A. Norman, 2006, Journal of medicinal chemistry.

Efficacy Growth Factor Signaling with Broad-Spectrum Antitumor ZD 4190 : An Orally Active Inhibitor of Vascular Endothelial

B. Curry, S. Wedge, J. Kendrew, 2000 .

78 ZD4054 specifically inhibits endothelin A receptor-mediated anti-apoptotic effects, but not endothelin B receptor-mediated pro-apoptotic effects

J. Curwen, Z. Howard, N. Curtis, 2004 .

The combination of the specific endothelin A receptor antagonist ZD4054 and submaximal bisphosphonate pamidronate prevents soft-tissue metastasis

J. Curwen, E. Thompson, E. Williams, 2007 .

Defining the basis of an operational model for enhanced efficacy of combination therapy using an endothelin receptor antagonist and chemotherapeutic agents

J. Nelson, J. Curwen, Jason M. D'Antonio, 2007 .

Role of the endothelin axis and its antagonists in the treatment of cancer

J. Curwen, M. Loizidou, B. Pflug, 2011, British journal of pharmacology.

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.

A. Rabow, G. Walker, R. A. Norman, 2016, Cancer research.

The contribution of VEGF signalling to fostamatinib‐induced blood pressure elevation

M. Braddock, J. Curwen, M. Skinner, 2014, British journal of pharmacology.

Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo.

Peter Ballard, Leonie Campbell, David Buttar, 2009, Bioorganic & medicinal chemistry letters.

Design, analysis and reporting of tumor models

J. Curwen, Robert Shaw, Sharon Miller, 2017, Lab Animal.

Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.

Paul R. J. Davey, James S. Scott, A. Bailey, 2019, Journal of medicinal chemistry.

Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents

M. Braddock, J. Curwen, J. Valentin, 2015, Pharmacology research & perspectives.

The VEGF receptor tyrosine kinase inhibitor AZD2171 inhibits VEGF signaling, angiogenesis, and tumor growth in vivo

S. Wedge, J. Kendrew, P. Plé, 2004 .

Abstract DDT01-03: Discovery and pre-clinical pharmacology of AZD9496: An oral, selective estrogen receptor down-regulator (SERD)

A. Rabow, D. M. Andrews, G. Walker, 2015 .

361 Preclinical activity of AZD0530, a novel, oral, potent and selective inhibitor of the Src family kinases

P. Plé, J. Curwen, V. Jacobs, 2004 .

Combinaison de n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide et d'un agent cytotoxique anti-mitotique pour le traitement du cancer

J. Curwen, D. Johnstone, F. T. Boyle, 2005 .